Clinuvel Pharmaceuticals Limited Stock price

Equities

CUV

AU000000CUV3

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
14.36 AUD +1.27% Intraday chart for Clinuvel Pharmaceuticals Limited +5.05% -10.25%
Sales 2024 * 89.47M 58.22M Sales 2025 * 101M 65.89M Capitalization 711M 463M
Net income 2024 * 34M 22.12M Net income 2025 * 37M 24.08M EV / Sales 2024 * 5.86 x
Net cash position 2024 * 187M 122M Net cash position 2025 * 216M 140M EV / Sales 2025 * 4.89 x
P/E ratio 2024 *
20.9 x
P/E ratio 2025 *
19.2 x
Employees -
Yield 2024 *
0.48%
Yield 2025 *
0.52%
Free-Float 79.56%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Clinuvel Pharmaceuticals Limited

1 day+1.27%
1 week+1.48%
Current month+4.97%
1 month+1.70%
3 months-11.14%
6 months-3.62%
Current year-10.25%
More quotes
1 week
13.53
Extreme 13.53
14.60
1 month
12.96
Extreme 12.96
15.25
Current year
12.96
Extreme 12.96
17.20
1 year
12.96
Extreme 12.96
21.53
3 years
12.96
Extreme 12.96
44.67
5 years
12.92
Extreme 12.92
45.88
10 years
1.30
Extreme 1.3
45.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 05-10-31
Director of Finance/CFO - 05-10-31
Chief Operating Officer - 06-12-31
Members of the board TitleAgeSince
Chief Executive Officer 61 05-10-31
Director/Board Member - 07-02-05
Director/Board Member - 18-01-28
More insiders
Date Price Change Volume
24-03-28 14.36 +1.27% 84 624
24-03-27 14.18 +3.13% 81,515
24-03-26 13.75 +0.73% 111,836
24-03-25 13.65 -1.09% 87,416
24-03-22 13.8 -2.47% 90,057

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Company's pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.18 AUD
Average target price
25.01 AUD
Spread / Average Target
+76.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Clinuvel Pharmaceuticals Limited - Australian S.E.